Therapeutic Candidate definition

Therapeutic Candidate means the plasmid, known as SB-509, that encodes a zinc finger DNA-binding protein designed to upregulate the expression of vascular endothelial growth factor (VEGF-A).
Sample 1Sample 2Sample 3
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research, or identified during the Tail End Period, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or its homologues or derivatives) shall be within the definition of Therapeutic Candidate (and vice-versa).
Sample 1Sample 2Sample 3
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research (whether pursuant to this Agreement or pursuant to the Novartis Angiogenesis Collaboration), or identified during the Tail End Period, by either Party, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice-versa). The rights of the Parties with respect to Therapeutic Candidates that are also Targets are as set forth in Section 2.4.
Sample 1Sample 2

Examples of Therapeutic Candidate in a sentence

  • We look forward to the rapid advancement of Xxxxx Therapeutics’ clinical pipeline and the opportunity to bring novel therapeutics to patients in need.” In a recent poster entitled “The Development of a xxXXX-based Therapeutic Candidate for Hepatocellular Carcinoma,” presented at the November, 2011 AACR-NCI-EORTC International [CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.


More Definitions of Therapeutic Candidate

Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research (whether pursuant to this Agreement or pursuant to the Novartis Angiogenesis Collaboration), or identified during the Tail End Period, by either Party, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice- versa). The rights of the Parties with respect to Therapeutic Candidates that are also Targets are as set forth in Section 2.4.
Sample 1
Therapeutic Candidate means any ZFP-containing molecule (including a Zinc Finger Nuclease or Zinc Finger Transcription Factor) that (a) [*] to a Collaboration Target, (b) is the subject of Sangamo Research Activities under the applicable Research Plan and (c) [*] under the applicable Research Plan. 1.208 “Therapeutic Field” means the treatment or prevention of disease in humans or animals in any and all indications. 1.209 “Third Party” means any Person other than a Party or an Affiliate of a Party. 1.210 “Third Party Distributor” means, with respect to a Product in any country, any Third Party that purchases its requirements for such Product in such country from Biogen or its Affiliates or Sublicensees and is appointed by Biogen or its Affiliate or Sublicensee as a distributor to distribute, market and resell such Product in such country, even if such Third Party is granted ancillary rights to Develop, package or obtain Regulatory Approval for such Product in order to distribute, market or sell such Product in such country. 1.211 “Trademarks” means all trademarks, service marks, trade names, service names, internet domain names, brand names, logos, protectable slogans and trade dress rights, whether registered or unregistered, and all applications, registrations and renewals thereof. 1.212 “Transition Plan” has the meaning set forth in Section 12.5(b) (Transition to Sangamo). 1.213 “Unauthorized Inventing Party” has the meaning set forth in Section 10.1(d) (Unauthorized Inventions). 1.214 “Unauthorized Inventions” has the meaning set forth in Section 10.1(d) (Unauthorized Inventions). 1.215 “United States” or “U.S.” means the United States of America, including its territories and possessions. 1.216 “Upfront Payment” has the meaning set forth in Section 9.1 (Upfront Payment). 1.217 “Upstream License” means any agreement between Sangamo (or any of its Affiliates) and any Third Party (such Third Party, an “Upstream Licensor”) under which such Third Party grants Sangamo a license under any of the Licensed Technology, but expressly 24 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Sample 1
Therapeutic Candidate means a peptide, protein or Genetic Material discovered, identified, produced or tested during the Research Period pursuant to the Research [*], or identified during the Tail End Period, by either Party, which meets the Success Criteria, and any homologues or derivatives thereof. For such purposes, it is understood that if a protein or peptide meets the Success Criteria, Genetic Material that codes for such protein or peptide (or homologues or derivatives of such Genetic Material) shall be within the definition of Therapeutic Candidate (and vice-versa). The rights of the Parties with respect to Therapeutic Candidates that are also Targets are as set forth in Section 2.4.
Sample 1
Therapeutic Candidate means any TransMab Antibody selected for Co-Development by the "parties" in accordance with Section 2.5.1.
Sample 1

Related to Therapeutic Candidate

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Diagnostic Product means In Vitro Diagnostics, In Vivo Diagnostic Agents and any product used for Diagnosis.

  • Licensed Compound means (a) 3,4-Diaminopyridine, the chemical structure of which is set forth on Exhibit B-2; and (b) any derivatives, isomers, metabolites, prodrugs, acid forms, base forms, salt forms, or modified versions of such compound in (a).

  • Therapeutic school means a residential group living facility:

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Therapeutic care means services provided by licensed or certified speech pathologists, Occupational Therapists and Physical Therapists.

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Therapeutic Equivalent means that a Covered Drug can be expected to produce essentially the same therapeutic outcome and toxicity.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Nicotine product means a product that contains nicotine and is not any of the following:

  • Biosimilar Product means, with respect to a Licensed Product in any country, any biosimilar product sold by a Third Party not authorized by or on behalf of Celgene, its Affiliates or Sublicensees, (a) that is a biosimilar biological product, as defined in 21 USC 379j-51 (or any successor or replacement thereof), a similar biological medicinal product, as defined in Annex I to Directive 2001/83/EC (or any successor or replacement thereof), or any similar biosimilar or generic product under the Laws of any country or jurisdiction, or (b) regarding which Regulatory Approval is obtained by referencing Regulatory Data of such Licensed Product.

  • Active Pharmaceutical Ingredient or “API” shall mean one or more of the following active pharmaceutical ingredients: tenofovir alafenamide (“TAF”), tenofovir disoproxil fumarate (“TDF”), elvitegravir (“EVG”), and cobicistat (“COBI”).

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • Opioid antagonist means a drug that binds to opioid

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Independent candidate means any candidate who claims not to be affiliated with a political party, and whose name has been certified on the office-type ballot at a general or special election through the filing of a statement of candidacy and nominating petition, as prescribed in section 3513.257 of the Revised Code.